Advanced search
Publication Cover
Modern Rheumatology Volume 31, 2021 - Issue 2
Journal homepage
169
Views
2
CrossRef citations to date
0
Altmetric
Rapid Communications

A simple screening test to assess risk of falls in Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study

Koei Oha Department of Orthopedics, Tokyo Women’s Medical University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-9061-0771
ORCID Icon,
Takefumi Furuyab Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7771-2813
ORCID Icon,
Eisuke Inouec Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, JapanORCID Iconhttps://orcid.org/0000-0002-1652-7769
ORCID Icon,
Eiichi Tanakab Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-6367-9386
ORCID Icon,
Katsunori Ikaria Department of Orthopedics, Tokyo Women’s Medical University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-9066-2005
ORCID Icon,
Atsuo Taniguchib Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-3248-1027
ORCID Icon,
Hisashi Yamanakab Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan;d Department of Rheumatology, Sanno Medical Center, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-8453-6731
ORCID Icon,
Ken Okazakia Department of Orthopedics, Tokyo Women’s Medical University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0003-1274-8406
ORCID Icon &
Masayoshi Harigaib Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-6418-2603
ORCID Icon show all
Pages 506-509 | Received 14 Feb 2020, Accepted 16 Mar 2020, Published online: 14 Apr 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Conflict of interest

T.F. has served on speakers’ bureaus for Ayumi Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corporation, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Taisho Pharmaceutical Co., Ltd. E.I. has received speaker’s fees from Bristol-Myers Squibb and Pfizer Japan, Inc. E.T. has received lecture fees or consulting fees from Abbvie, Asahi Kasei Pharma Co., Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo Co., Eisai Pharmaceutical, Janssen Pharmaceutical K.K., Nippon Kayaku, Pfizer, Takeda Pharmaceutical, Taisho Toyama Pharmaceutical Co., and UCB Pharma. A.T. has served on speakers’ bureaus for Pfizer Japan, Inc. K.I. has received speaker’s fees from Asahi Kasei Pharma Corp., Astellas Pharma Inc., AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eis, ai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma, Ltd. and UCB Japan Co., Ltd. H.Y. has received a research grant from and has served on speakers’ bureaus for AbbVie, Astellas, Ayumi, Behringer, Bristol-Meyers, Chugai, Daiichi-Sankyo, Eisai, Kaken, Nippon-Shinyaku, Novartis, Ono, Pfizer, Taisyo-Toyama, Takeda, Tanabe-Mitsubishi, Teijin Pharma, Torii, UCB, and YLbio. M.H. has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma, Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekiui Medical, Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma, Ltd. MH has received speaker’s fees from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. MH is also a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd. and Teijin Pharma.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
There are no offers available at the current time.

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.